Anti-Viral Patent Granted in Europe for RECCE® Anti-Infectives
Sydney Australia, 30 March 2021: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing New Classes of Synthetic Anti-infectives, is pleased to announce the European Patent Office has granted Patent Family 3 “Anti-Virus Agent For Treatment Of Viral Infections”, furthering marketing and manufacturing monopolies to February 2037.
The European Patent Office granted claims relate to RECCE® 327 (R327) and Anti-Viral formulation RECCE® 529 (R529), most notably:
- Composition/method of manufacture of RECCE® anti-infectives
- Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses
- Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
Europe represents one of the largest anti-viral therapies markets in the world, valued at US$11.40 billion (AU$14.93 billion) in 2019 and expected to reach US$21.12 billion (AU $27.66 billion) by 2027, with a CAGR of 8.1% during 2020-2027.[i]
This is the second Patent in Family 3 to be granted to the Company following its recent patent grant in Japan, with applications among other major pharmaceutical markets around the world in their advanced stages of independent patent reviews.
Chief Executive Officer, James Graham said: “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us. Our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens”.
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE® 327, RECCE® 435, and RECCE® 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
Patented lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE® 435, has been formulated for oral use.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer drug candidate for treating sepsis currently in development.
Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.
[i] Pharmaceutical Market in Europe - https://bit.ly/3dfZ1HC
